Several commonly prescribed RA drugs can be self-injected at home, often using either a prefilled syringe or an auto-injector ...

Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...

Blackford Capital has announced a strategic investment in Texas Injection Molding, providing the Houston-based manufacturer with capital for continued expansion and access to Blackford's expertise in ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, discusses the ...

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections. The drug, called enlicitide, slashes levels ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved ...

With its biosimilars business thriving, Amgen is in a unique position to comment on U.S. biosimilar policy as the current administration introduces reforms to increase the availability of the copycat ...